#LiverCancer
▶️The impact of the COVID-19 pandemic on hepatocellular carcinoma diagnosis and treatment in Japan: A multicenter collaborative observational study

👉doi.org/10.1111/hepr.1…

#HepatolRes #LiverTwitter Wiley Clinical Health

This work was done by Natsuko Kobayashi 兵庫医科大学 肝胆膵内科(Hyogo College of Medicine) .
We wholeheartedly congratulate them! 👏

Wiley Clinical Health

#Steatohepatitis
▶️Metabolic dysfunction-associated steatotic liver disease criteria may underestimate the number of lean female nonalcoholic fatty liver disease patients with significant liver fibrosis

👉doi.org/10.1111/hepr.1…

#HepatolRes #LiverTwitter Wiley Clinical Health

#ReviewArticle
▶️Natural killer group 2D-major histocompatibility complex class I polypeptide-related sequence A activation enhances natural killer cell-mediated immunity against HCC: A review

👉doi.org/10.1111/hepr.1…

#HepatolRes #LiverTwitter Wiley Clinical Health

From the Editor of Hepatol Res

✅Quantification of donor-derived cell-free DNA by next-generation sequencer

☝Donor-derived cell-free DNA
= sensitive biomarker for graft injuries in liver transplantation

From the Editor of Hepatol Res

✅Genome-wide DNA methylation analysis
⇒distinct DNA methylation during development of cryptogenic HCC without a background of SLD, viral hepatitis, or ALD.
🔥DNA hypermethylation of ADCY5
🔥DNA hypomethylation of MICAL2 and PLEKHG2

From the Editor of Hepatol Res

During the COVID-19 lockdown
👉Physical activity⇩, dietary habits⇨
👉Men: body fat⇧ ＆visceral fat⇧
👉Women: skeletal muscle⇩＆ hepatic steatosis⇧

🔥Need for gender-specific approaches for CLD to avoid exacerbation or comorbidity of SLD!

From the Editor of Hepatol Res

✅ age ≥65 years = The only factor independently associated with eGFR⇩ after 2 years of ETV or TAF for Hep B

👉Long-term NUC to patients aged ≥65 years should be carefully monitored for renal impairment.

From the Editor of Hepatol Res

✅MASLD: Review
✅Pathogenetic role of NH3
✅Serum RNase L in HepB
✅Effect of NUC on renal function
✅SLD & extrahepatic cancer
✅SLD & muscle during COVID-19
✅DNA methylation in HCC
✅Graft monitoring using cell-free DNA
✅Cabo after IO for HCC

From the Editor of Hepatol Res

✅Even when the blood NH3 is normal in cirrhosis

　👉Abnormal NH3 metabolism is considered if the BCAA to tyrosine ratio is low

　🔥 the latency period of abnormal NH3 metabolism！

This work was done by Tadashi Namisaki 奈良県立医科大学　消化器・代謝内科
and we extend our heartfelt congratulations! 👏

Wiley Clinical Health

#Editorial
▶️Noninvasive assessment of portal hypertension based on the Baveno VII criteria

👉doi.org/10.1111/hepr.1…

#HepatolRes #LiverTwitter Wiley Clinical Health

From the Editor of Hepatol Res

🔥MAFLD = independently and directly associated with the recurrence of esophageal cancer after ESD along with drinking and smoking.

👉Recurrence is significantly higher in the non-obese than in obese MAFLD among abstainers/non-drinkers!

From the Editor

🗝Presence of autoantibodies at baseline ⇒ risk of irAE in patients receiving Atezo+Bev for HCC

🔥Autoantibodies at baseline = risk for irAE HR 3.7
👉Patients with autoantibodies at baseline are at high risk of irAE development and require cautious follow-up！

From the Editor

Simple score FLA-1 predicts HCC among HBV on NUC!!
🗝FIB-4 ≥1.58 and ALT≥31 at year 1 after NUC = high incidence of HCC.
👉FAL-1 score = applicable number of FIB-4 ≥1.58 and ALT ≥31
👉HCC @ 10 years = 0.7%, 9.8%, and 24.1% for scores 0, 1, and 2, respectively

✅New concept in FLD
✅FIB-4 & ALT predict HCC in Hep B on NUC
✅HEV vaccination for Hep B
✅TSH predicts Hep B-ACLF
✅Autoantibody ＆ irAE in Atezo+Bev
✅ARHGAP1 promotes HCC
✅MSH6/MSH2 & HCC
✅non-obese MASLD & recurrence of esophageal cancer

and more!

#ShortCommunication
▶️Impact of post-progression survival in second-line treatment with molecular target agents for unresectable hepatocellular carcinoma

👉doi.org/10.1111/hepr.1…

#HepatolRes #LiverTwitter Wiley Clinical Health

#LiverBiology
▶️Galectin-3 in biliary atresia and other pediatric cholestatic liver diseases

👉doi.org/10.1111/hepr.1…

#HepatolRes #LiverTwitter Wiley Clinical Health

#LiverCancer
▶️Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study

👉doi.org/10.1111/hepr.1…

#HepatolRes #LiverTwitter Wiley Clinical Health